U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389876) titled 'Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma' on Jan. 26.
Brief Summary: This study is an open-label, multi-cohort real-world research that explores the efficacy and safety of different second-line treatment regimens for gastric/gastroesophageal junction adenocarcinoma that has failed first-line fluoropyrimidine, platinum-based chemotherapy combined with immunotherapy.
Study Start Date: Sept. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Gastric Cancer
Second-line Treatment
Intervention:
DRUG: Albumin-bound Paclitaxel
This is a prospective observational s...